ContractLicense and Collaboration Agreement • March 20th, 2024 • BioNTech SE • Biological products, (no disgnostic substances) • New York
[***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) the type of information that the Registrant treats as private or confidential.
ContractLicense and Option Agreement • March 20th, 2024 • BioNTech SE • Biological products, (no disgnostic substances)
[***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type of information that the Registrant treats as private or confidential.
COLLABORATION, LICENSE AND OPTION AGREEMENTCollaboration, License and Option Agreement • March 20th, 2024 • BioNTech SE • Biological products, (no disgnostic substances) • England and Wales
This COLLABORATION, LICENSE AND OPTION AGREEMENT (this "Agreement") is entered into this 26th day of October, 2023 (the "Execution Date"), by and between
LICENSE AND COLLABORATION AGREEMENT (TROP2) by and between DUALITY BIOLOGICS (SUZHOU) CO. LTD. and BIONTECH SE dated as of August 4, 2023License and Collaboration Agreement • March 20th, 2024 • BioNTech SE • Biological products, (no disgnostic substances) • New York
This License and Collaboration Agreement (the “Agreement”) is entered into as of August 4, 2023 (the “Effective Date”), by and between Duality Biologics (Suzhou) Co. Ltd., a corporation organized and existing under the laws of the People’s Republic of China (“Duality”), having a place of business at Unit 1105-1106, No 868 Ying Hua Road, Pudong New District, Shanghai, China, and BioNTech SE, a company organized and existing under the laws of Germany, having a place of business at An der Goldgrube 12, D-55131 Mainz, Germany (“Licensee”).
AMENDMENT No. 1 to the License and Collaboration Agreement between BioNTech SE and OncoC4, Inc.License and Collaboration Agreement • March 20th, 2024 • BioNTech SE • Biological products, (no disgnostic substances)
This Amendment No. 1 to the License and Collaboration Agreement (this “Amendment”) is entered into as of February 14, 2024 (“Amendment No. 1 Effective Date”) by and between BioNTech SE, a public limited company in the form of a Societas Europaea organized under the laws of the Federal Republic of Germany, with its corporate seat at An der Goldgrube 12 55131 Mainz, registered with the commercial register of the Local Court of Mainz under HRB 48720 (“BioNTech”), and OncoC4, Inc., a Delaware corporation having business offices at 9640 Medical Center Drive, Rockville, MD 20850 (“OncoC4”). OncoC4 and BioNTech are each referred to herein, individually, as a “Party” and, collectively, as the “Parties.”
LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • March 20th, 2024 • BioNTech SE • Biological products, (no disgnostic substances)
This License and Collaboration Agreement (this “Agreement”), effective as of March 17, 2023 (the “Execution Date”), is entered into by and between BioNTech SE, a public limited company in the form of a Societas Europaea organized under the laws of the Federal Republic of Germany, with its corporate seat at An der Goldgrube 12 55131 Mainz, registered with the commercial register of the Local Court of Mainz under HRB 48720 (“BioNTech”), and OncoC4, Inc., a Delaware corporation having business offices at 9640 Medical Center Drive, Rockville, MD 20850 (“OncoC4”). OncoC4 and BioNTech are each referred to herein, individually, as a “Party” and, collectively, as the “Parties.”
